These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 27206758)

  • 41. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial.
    Lee JH; Park JG; Lim SH; Kim JY; Ahn KY; Kim MY; Park YM
    Dermatol Surg; 2006 May; 32(5):626-31. PubMed ID: 16706756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination of Oral Tranexamic Acid with Topical 3% Tranexamic Acid versus Oral Tranexamic Acid with Topical 20% Azelaic Acid in the Treatment of Melasma.
    Malik F; Hanif MM; Mustafa G
    J Coll Physicians Surg Pak; 2019 Jun; 29(6):502-504. PubMed ID: 31133144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparing the efficacy of Myjet-assisted tranexamic acid and vitamin C in treating melasma: A split-face controlled trial.
    Zhao H; Li M; Zhang X; Li L; Yan Y; Wang B
    J Cosmet Dermatol; 2020 Jan; 19(1):47-54. PubMed ID: 31479196
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral tranexamic acid, hydroquinone 4% and low-fluence 1064 nm Q-switched Nd:YAG laser for mixed melasma: Clinical and dermoscopic evaluation.
    Elkamshoushi AM; Romisy D; Omar SS
    J Cosmet Dermatol; 2022 Feb; 21(2):657-668. PubMed ID: 33826785
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparing the efficacy of topical hydroquinone 2% versus intradermal tranexamic acid microinjections in treating melasma: a split-face controlled trial.
    Saki N; Darayesh M; Heiran A
    J Dermatolog Treat; 2018 Jun; 29(4):405-410. PubMed ID: 29027510
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Prospective Randomized Controlled Study of Oral Tranexamic Acid for the Prevention of Postinflammatory Hyperpigmentation After Q-Switched 532-nm Nd:YAG Laser for Solar Lentigines.
    Rutnin S; Pruettivorawongse D; Thadanipon K; Vachiramon V
    Lasers Surg Med; 2019 Dec; 51(10):850-858. PubMed ID: 31302943
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The optimal dose of oral tranexamic acid in melasma: A network meta-analysis.
    Wang WJ; Wu TY; Tu YK; Kuo KL; Tsai CY; Chie WC
    Indian J Dermatol Venereol Leprol; 2023; 89(2):189-194. PubMed ID: 36332095
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic efficacy and safety of oral tranexamic acid 250 mg once a day versus 500 mg twice a day: a comparative study.
    Chowdhary B; Mahajan VK; Mehta KS; Chauhan PS; Sharma V; Sharma A; Vashist S; Kumar P
    Arch Dermatol Res; 2021 Mar; 313(2):109-117. PubMed ID: 32356007
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tranexamic acid in melasma: A focused review on drug administration routes.
    Konisky H; Balazic E; Jaller JA; Khanna U; Kobets K
    J Cosmet Dermatol; 2023 Apr; 22(4):1197-1206. PubMed ID: 36606378
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation.
    Desai S; Ayres E; Bak H; Manco M; Lynch S; Raab S; Du A; Green D; Skobowiat C; Wangari-Talbot J; Zheng Q
    J Drugs Dermatol; 2019 May; 18(5):454-459. PubMed ID: 31141852
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of combination therapy of broadband light and intradermal injection of tranexamic acid in the treatment of chloasma.
    Jia Z; Tian K; Zhong Y; Wang X; Gao S; Xu W; Li K; Wu L
    J Cosmet Dermatol; 2023 May; 22(5):1536-1544. PubMed ID: 36718828
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.
    Chan R; Park KC; Lee MH; Lee ES; Chang SE; Leow YH; Tay YK; Legarda-Montinola F; Tsai RY; Tsai TH; Shek S; Kerrouche N; Thomas G; Verallo-Rowell V
    Br J Dermatol; 2008 Sep; 159(3):697-703. PubMed ID: 18616780
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of oral tranexemic acid in refractory melasma: A clinico-immuno-histopathological study.
    Nagaraju D; Bhattacharjee R; Vinay K; Saikia UN; Parsad D; Kumaran MS
    Dermatol Ther; 2018 Sep; 31(5):e12704. PubMed ID: 30253023
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic efficacy and safety of oral tranexamic acid and that of tranexamic acid local infiltration with microinjections in patients with melasma: a comparative study.
    Sharma R; Mahajan VK; Mehta KS; Chauhan PS; Rawat R; Shiny TN
    Clin Exp Dermatol; 2017 Oct; 42(7):728-734. PubMed ID: 28649780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel dissolving microneedles preparation for synergistic melasma therapy: Combined effects of tranexamic acid and licorice extract.
    Xing M; Wang X; Zhao L; Zhou Z; Liu H; Wang B; Cheng A; Zhang S; Gao Y
    Int J Pharm; 2021 May; 600():120406. PubMed ID: 33711468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The efficacy of oral vs different dilutions of intradermal tranexamic acid microinjections in melasma-A randomized clinical trial.
    El Hadidi H; Mosaad R; Ragab N
    Dermatol Ther; 2021 May; 34(3):e14924. PubMed ID: 33651442
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of tranexamic acid in the treatment of adult melasma: An updated meta-analysis of randomized controlled trials.
    Feng X; Su H; Xie J
    J Clin Pharm Ther; 2021 Oct; 46(5):1263-1273. PubMed ID: 33959984
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of oral tranexamic acid as a novel treatment for melasma with a high benefit-risk ratio.
    Simpson J; Peng L; Ting W
    J Cosmet Dermatol; 2022 Nov; 21(11):6393-6399. PubMed ID: 35972476
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of efficacy and safety of tranexamic acid mesotherapy versus oral tranexamic acid in patients with melasma undergoing Q-switched fractional 1064-nm Nd:YAG laser: A blinded RCT and follow-up.
    Behrangi E; Shemshadi M; Ghassemi M; Goodarzi A; Dilmaghani S
    J Cosmet Dermatol; 2022 Jan; 21(1):279-289. PubMed ID: 34724323
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A pilot study of oral tranexamic acid and Glycyrrhizin compound in the treatment of recalcitrant Riehl's melanosis.
    Xu Z; Xing X; Zhang C; Chen L; Flora Xiang L
    J Cosmet Dermatol; 2019 Feb; 18(1):286-292. PubMed ID: 30341831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.